期刊文献+

新疆乌鲁木齐汉族、维吾尔族女性骨质疏松患者骨生化指标和血脂水平研究 被引量:4

Study of the bone metabolic and biochemical markers and serum lipid levels in Han and Uygur osteoporosis women in Urumqi of Xinjiang
下载PDF
导出
摘要 目的 通过分析新疆乌鲁木齐地区汉族与维吾尔族女性骨质疏松患者骨代谢和血脂的水平,探讨血脂与骨质疏松症的关系。方法 选择2008年5月至2010年2月期间,我院就诊的女性骨质疏松患者134例,其中,汉族88例,维吾尔族46例,对比分析两组体重指数、血清电解质、部分骨生化标志物以及血脂水平。结果两组体重指数、血清Ca、P、Mg水平无统计学差异(P>0.05);骨特异性碱性磷酸酶(BAP)、骨钙素(BGP)水平,维族组高于汉族(P<0.05),抗酒石酸酸性磷酸酶5b(TRACP-5b)水平两组无显著性差异(P>0.05);高密度脂蛋白、总胆固醇、低密度脂蛋白、甘油三酯和载脂蛋白α,两组无明显统计学差异(P>0.05);高密度脂蛋白低于正常值的维族患者有6例,汉族有25例,两组具有统计学差异(P<0.05)。结论 通过影响成骨细胞的骨代谢水平,高密度脂蛋白异常可能是新疆乌鲁木齐地区汉族女性骨质疏松患者的危险因素之一。 Objective To explore the relationship between serum lipid level and osteoporosis by analyzing the bone metabolic and biochemical markers and lipid levels in Han and Uygur osteoporosis women in Urumqi of Xinjiang. Methods One hundred and thirty-four osteoporotic women diagnosised in our hospital from May 2108 to Feb 2010 were included in the study. Among those, 88 patients were Han and 46 were Uygur.nationality. The body mass index (BMI) , serum electrolytes, bone biochemical markers, and serum lipid levels of patients between the Han and Uygur group were analyzed and compared. Results There were no significant differences in BMI, serum Ca, P, and Mg levels between Han patients and Uygur patients. The levels of bone specific alkaline phosphase (BAP) and BGP in.Uygur patients were significantly higher than those in Han patients ( P 〈 0.05 ). There were no significant statistical differences in TRACP-Sb between the two groups (P 〉 0.05). There were also no significant statistical differences in levels of serum total cholesterol, low density lipoprotein, triglycerides, and apo-lipoprotein between the two groups (P 〉 0.05). The levels of high density lipoprotein (HDL) in 6 Uygur patients and 25 Han patients were under the normal level. The statistical significance existed between the two groups (P 〈 0. 05). Conclusion By influencing bone metabolic level of osteoblasts, HDL abnormality may be one of the osteoporosis risk factors for Han women.
出处 《中国骨质疏松杂志》 CAS CSCD 2010年第11期813-816,共4页 Chinese Journal of Osteoporosis
关键词 骨质疏松 骨代谢生化指标 高密度脂蛋白胆固醇 Osteoporosis Bone metabolic and biochemical markers High-density lipoprotein cholesterol
  • 相关文献

参考文献10

  • 1Pritchett JW.Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.Clin Orthop Relat Res,2001,(386):173-178. 被引量:1
  • 2李梅,孟迅吾,邢小平,周学瀛,夏维波,胡莹莹,刘怀成.阿仑膦酸钠治疗37例绝经后骨质疏松症的疗效及观察[J].基础医学与临床,2003,23(3):302-305. 被引量:11
  • 3Adami S,Braga V,Guidi G,et al.Chronic intravenous aminobispbosphonate therapy increases high-density lipoprotein cholesterol and decreases low-lipoprotein cholesterol.J Bone Miner Res,2000,15:599-604. 被引量:1
  • 4Bennett JH,Joyner CJ,Triffitt JT,et al.Adipocytic cells cultured from marrow have osteogenic potential.J Cell Sci,1991,99(Pt1):131-139. 被引量:1
  • 5Diascro DDJr,Vogel RL,Johnson TE,et al.High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells.Bone Miner Res,1998,13(1):96-106. 被引量:1
  • 6Tintut Y,Morony S,Demer LL.Hyperlip idemia promotes osteoclastic potential of bone marrow cells ex vlvo.Arterioscler Thromb Vasc Biol,2004,24(2):6-10. 被引量:1
  • 7Yamaguchi T,Sugimoto T,Yano S,et al.Plasma lipids and osteoporosis in postmenopausal women.Endocr J,2002,49(2):211-217. 被引量:1
  • 8薛月华,谢匡成,许翔,许雯,张黎明.绝经期冠心病妇女血脂水平与骨密度的研究[J].中国骨质疏松杂志,2008,14(6):388-390. 被引量:13
  • 9Majima T,Shimatsu A,Komatsu Y,et al.Increased bone turnover in patients with hypercholesterolemia.Endocr J,2008,55(1):143-151. 被引量:1
  • 10Nenonen A,Cheng S,Ivaska KK,et al.Serum TRACP 5b is a useful marker for monitoring alendronate treatment:comparison with other markers of bone turnover.J Bone Miner Res,2005,20(10):1804-1812. 被引量:1

二级参考文献19

  • 1李万根,陈澍,武兆忠,宫雅南,朱沛庄,邓煜辉.绝经后妇女血脂水平与骨密度的关系[J].中国骨质疏松杂志,2004,10(2):193-194. 被引量:13
  • 2张咏梅,林华.冠心病和骨质疏松[J].中国骨质疏松杂志,2005,11(2):266-268. 被引量:23
  • 3Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of Alendronate: 7-year treaunent of postmenopausal osteoporotic women[J]. J Clin Endocrinol Metab, 2000,85:3109- 3115. 被引量:1
  • 4Hernandez CJ, Boaupre GS, Marcus R, et al. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during Alendronate treaunentE[J]. Bone, 2001,29:511- 516. 被引量:1
  • 5Liberman UA, Weiss SR, Broll J, et al . Effect of oral Alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis[J]. N Engl J Med, 1995,333:1437- 1443. 被引量:1
  • 6Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of Alendronate on fracture-related healthcare utilization and costs:the fracture intervention trial[J]. Osteoporos Int, 2001,12:654 - 660. 被引量:1
  • 7Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of Alendronate on risk of fracture in women with existing vertebral fxacture[J]. Lancet, 1996,348:1535 - 1541. 被引量:1
  • 8Watts NB, Jenkins DK, Visor JM, etal. Comparison of bone and total Alakine Phosphatase and bone mineral density in postmenopausal osteoporotic women treated with Alendronate [J].Osteoporos Int, 2001,12:279 - 288. 被引量:1
  • 9Bauer DC, BlackD, Ensrud K, etal. Upper gastrointestinal tract safety profile of Alendronate : The fracture intervention trial[J]. Arch Intern Med, 2000,160:517- 525. 被引量:1
  • 10Farwell WR, Sesso HD, Buring JE, et al. Min-high-deasity lipoprotein clolesterol versus low-density lipoprotein cholesterd as a risk facter for a first nonfatd mydocardial. Am J cardiol, 2005, 96 (8): 129-134. 被引量:1

共引文献22

同被引文献45

  • 1陈泽君,黄颂敏,樊文星,唐万欣,刘芳,邱红渝.高糖刺激血管平滑肌细胞表达cbfα-1和OC的实验研究[J].四川大学学报(医学版),2010,41(5):784-788. 被引量:3
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8240
  • 3Masse PG,Tranchant CC,Dosy J,et al. Coexistence of osteoporo-sis and cardiovascular disease risk factors in apparently healthy,untreated postmenopausal women [J]. Int J Vitam Nutr Res,2005,75(2):97-106. 被引量:1
  • 4Adami S,Braga V,Guidi G,et al. Chronic intravenous aminobi-sphosphonate therapy increases high-density lipoprotein cholester-ol and decreases low-lipoprotein cholesterol [J]. J Bone MinerRes,2000,15(3):599-604. 被引量:1
  • 5Kanis J A, Adams J, Borgstrom F,et al. The cost-effectiveness ofalendronate in the management of osteoporosis[J]. Bone,2008,42(1):4-15. 被引量:1
  • 6Escudero ND, Mandalunis PM. Influence of bisphosphonate treat-ment on medullary macrophages and osteoclasts:an experimentalstudy [J]. Bone Marrow Res, 2012,2012; 1-8. 被引量:1
  • 7Eslami B?Zhou S,Van Eekeren I, et al. Reduced osteoclastogene-sis and RANKL expression in marrow from women taking alendr-onate[J]. Calcif Tissue Int,2011,88(4):272-280. 被引量:1
  • 8Migliaccio S,Greco EA,Fornari R,et al. Is obesity in women pro-tective against osteoporosis? [J]. Diabetes Metab Syndr Obes,2011,4:273-282. 被引量:1
  • 9Ackert-Bicknell CL. HDL cholesterol and bone mineral density:isthere a genetic link? [J]. Bone,2012,50(2):525-533. 被引量:1
  • 10Jφrgensen NR,Schwarz P. Osteoporosis in chronic obstructive pulmonary disease patients[J].Curr Opin Puln Med,2008.122-127. 被引量:1

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部